Pharmaceutical company Cipla Limited (BSE:500087) (NSE:CIPLA EQ) revealed on Tuesday that its Cipla Gulf FZ LCC subsidiary is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia and New Zealand.

Under the terms of this strategic alliance, Cipla Gulf will be responsible for commercialization of patented biosimilars of leading products covering therapeutic categories across immunology, osteoporosis, oncology and ophthalmology.

The products are developed and manufactured by Alvotech and will be distributed by Cipla Gulf through Australia and New Zealand distribution networks. These innovative products recorded USD700m in aggregate 2020 sales in Australia.

Alvotech is a biopharmaceutical company focused on the development and manufacture of high quality biosimilars for global markets.